Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Patents on Anti-Cancer Drug Discovery
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

Background

Osteosarcoma is a highly invasive bone marrow stromal tumor with limited treatment options. Oxidative stress plays a crucial role in the development and progression of tumors, but the underlying regulatory mechanisms are not fully understood. Recent studies have revealed the significant involvement of UBE2L3 in oxidative stress, but its specific role in osteosarcoma remains poorly investigated.

Objective

This study aimed to explore the molecular mechanisms by which UBE2L3 promotes oxidative stress-regulated necroptosis to accelerate the progression of osteosarcoma using cell experiments.

Methods

Human osteoblast hFOB1.19 cells and various human osteosarcoma cell lines (MG-63, U2OS, SJSA-1, HOS, and 143B) were cultured . Plasmids silencing UBE2L3 and negative control plasmids were transfected into U2OS and HOS cells. The cells were divided into the following groups: U2OS cell group, HOS cell group, si-NC-U2OS cell group, si-UBE2L3-U2OS cell group, si-NC-HOS cell group, and si-UBE2L3-HOS cell group. Cell viability and proliferation capacity were measured using the Tunnel method and clonogenic assay. Cell migration and invasion abilities were assessed by Transwell and scratch assays. Cell apoptosis was analyzed by flow cytometry, and ROS levels were detected using immunofluorescence. The oxidative stress levels in various cell groups and the expression changes of necroptosis-related proteins were assessed by PCR and WB. Through these experiments, we aim to evaluate the impact of oxidative stress on necroptosis and uncover the specific mechanisms by which targeted regulation of oxidative stress promotes tumor cell necroptosis as a potential therapeutic strategy for osteosarcoma.

Results

The mRNA expression levels of UBE2L3 in human osteosarcoma cell lines were significantly higher than those in human osteoblast hFOB1.19 cells ( <0.01). UBE2L3 expression was significantly decreased in U2OS and HOS cells transfected with si-UBE2L3, indicating the successful construction of stable cell lines with depleted UBE2L3. Tunnel assay results showed a significant increase in the number of red fluorescent-labeled cells in si-UBE2L3 groups compared to si-NC groups in both cell lines, suggesting a pronounced inhibition of cell viability. Transwell assay demonstrated a significant reduction in invasion and migration capabilities of si-UBE2L3 groups in osteosarcoma cells. The clonogenic assay revealed significant suppression of proliferation and clonogenic ability in both U2OS and HOS cells upon UBE2L3 knockdown. Flow cytometry confirmed that UBE2L3 knockdown significantly enhanced apoptosis in U2OS and HOS cells. Immunofluorescence results showed that UBE2L3 silencing promoted oxidative stress levels in osteosarcoma cells and facilitated tumor cell death. WB analysis indicated a significant increase in phosphorylation levels of necroptosis-related proteins, RIP1, RIP3, and MLKL, in both osteosarcoma cell lines after UBE2L3 knockdown. In addition, the expression of necrosis-associated proteins was inhibited by the addition of the antioxidant N-acetylcysteine (NAC).

Conclusion

UBE2L3 is upregulated in osteosarcoma cells, and silencing of UBE2L3 promotes oxidative stress in these cells, leading to enhanced necroptosis and delayed progression of osteosarcoma.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928297557240212112531
2024-02-21
2025-01-06

  • From This Site

    /content/journals/pra/10.2174/0115748928297557240212112531
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WuX. WangJ. HeD. Establishment and validation of a competitive risk model for predicting cancer-specific survival in patients with osteosarcoma: A population-based study.J. Cancer Res. Clin. Oncol.202314917153831539410.1007/s00432‑023‑05320‑x37639006
     [Google Scholar]
  2. XuY. ShiF. ZhangY. YinM. HanX. FengJ. WangG. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors.Int. J. Cancer2023154222624010.1002/ijc.3469437596989
     [Google Scholar]
  3. ShaoZ. BiS. Studies related to osteosarcoma and metabolism from 1990 to 2022: A visual analysis and bibliometric study.Front. Endocrinol.202314114474710.3389/fendo.2023.114474736950694
     [Google Scholar]
  4. Almansa-GómezS. Prieto-RuizF. CansadoJ. MadridM. Autophagy modulation as a potential therapeutic strategy in osteosarcoma: Current insights and future perspectives.Int. J. Mol. Sci.202324181382710.3390/ijms24181382737762129
     [Google Scholar]
  5. MengjunMA. HongyuLI . Application of anti-SIRPA antibody combined with arginase in preparation of osteosarcoma treatment drug.CN11706501520232023-11-17.
  6. LilienthalI. HeroldN. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: A review of current and future strategies.Int. J. Mol. Sci.20202118688510.3390/ijms2118688532961800
     [Google Scholar]
  7. LiJ. YangZ. LiY. XiaJ. LiD. LiH. RenM. LiaoY. YuS. ChenY. YangY. ZhangY. Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment.Oncotarget2016728447634477810.18632/oncotarget.820627007056
     [Google Scholar]
  8. MengQ. ZhangW. XuX. LiJ. MuH. LiuX. QinL. ZhuX. ZhengM. The effects of TRAF6 on proliferation, apoptosis and invasion in osteosarcoma are regulated by miR-124.Int. J. Mol. Med.20184152968297610.3892/ijmm.2018.345829436576
     [Google Scholar]
  9. YangS. XiaoH. SunY. CaoL. Zeylenone synergizes with cisplatin in osteosarcoma by enhancing DNA damage, apoptosis, and necrosis via the Hsp90/ AKT / GSK3β and Fanconi anaemia pathway.Phytother. Res.202135105899591810.1002/ptr.729934585447
     [Google Scholar]
  10. HuangC. LinZ.J. LeeC.J. LaiW.H. ChenJ.C. HuangH.C. ε-Viniferin and α-viniferin alone or in combination induced apoptosis and necrosis in osteosarcoma and non-small cell lung cancer cells.Food Chem. Toxicol.202115811261710.1016/j.fct.2021.11261734728247
     [Google Scholar]
  11. TaoN.N. ZhangZ.Z. RenJ.H. ZhangJ. ZhouY.J. Wai WongV.K. Kwan LawB.Y. ChengS.T. ZhouH.Z. ChenW.X. XuH.M. ChenJ.   Overexpression   of   ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3β/p65 pathway.Cancer Lett.202048111410.1016/j.canlet.2020.03.02832268166
     [Google Scholar]
  12. Reyes-HernándezO.D. Mejía-GarcíaA. Sánchez-OcampoE.M. Cabañas-CortésM.A. RamírezP. Chávez-GonzálezL. GonzalezF.J. ElizondoG. Ube2l3 gene expression is modulated by activation of the aryl hydrocarbon receptor: Implications for p53 ubiquitination.Biochem. Pharmacol.201080693294010.1016/j.bcp.2010.05.00720478272
     [Google Scholar]
  13. HouX. YangS. YinJ. Blocking the REDD1/TXNIP axis ameliorates LPS-induced vascular endothelial cell injury through repressing oxidative stress and apoptosis.Am. J. Physiol. Cell Physiol.20193161C104C11010.1152/ajpcell.00313.201830485138
     [Google Scholar]
  14. WangH. LiJ. LiX. Construction and validation of an oxidative-stress-related risk model for predicting the prognosis of osteosarcoma.Aging202315114820484310.18632/aging.20476437285835
     [Google Scholar]
  15. GandhiD. NaoghareP.K. BafanaA. KannanK. SivanesanS. Fluoride-induced oxidative and inflammatory stress in osteosarcoma cells: Does it affect bone development pathway?Biol. Trace Elem. Res.2017175110311110.1007/s12011‑016‑0756‑627234253
     [Google Scholar]
  16. YaoZ.K. JeanY.H. LinS.C. LaiY.C. ChenN.F. TsengC.C. ChenW.F. WenZ.H. KuoH.M. Manoalide induces intrinsic apoptosis by oxidative stress and mitochondrial dysfunction in human osteosarcoma cells.Antioxidants2023127142210.3390/antiox1207142237507960
     [Google Scholar]
  17. TornínJ. VillasanteA. Solé-MartíX. GinebraM.P. CanalC. Osteosarcoma tissue-engineered model challenges oxidative stress therapy revealing promoted cancer stem cell properties.Free Radic. Biol. Med.202116410711810.1016/j.freeradbiomed.2020.12.43733401009
     [Google Scholar]
  18. YangJ. ZhangA. LuoH. MaC. Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma.Sci. Rep.2022121127910.1038/s41598‑022‑05341‑535075228
     [Google Scholar]
  19. ChenC. XieL. RenT. HuangY. XuJ. GuoW. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.Cancer Lett.202150011010.1016/j.canlet.2020.12.02433359211
     [Google Scholar]
  20. BeirdH.C. BielackS.S. FlanaganA.M. GillJ. HeymannD. JanewayK.A. LivingstonJ.A. RobertsR.D. StraussS.J. GorlickR. Osteosarcoma.Nat. Rev. Dis. Primers2022817710.1038/s41572‑022‑00409‑y36481668
     [Google Scholar]
  21. MeltzerP.S. HelmanL.J. New horizons in the treatment of osteosarcoma.N. Engl. J. Med.2021385222066207610.1056/NEJMra210342334818481
     [Google Scholar]
  22. HeF. ZhangW. ShenY. YuP. BaoQ. WenJ. HuC. QiuS. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis.Int. J. Surg.201636Pt A28329210.1016/j.ijsu.2016.11.01627840310
     [Google Scholar]
  23. GillJ. GorlickR. Advancing therapy for osteosarcoma.Nat. Rev. Clin. Oncol.2021181060962410.1038/s41571‑021‑00519‑834131316
     [Google Scholar]
  24. ZhaoX. WuQ. GongX. LiuJ. MaY. Osteosarcoma: A review of current and future therapeutic approaches.Biomed. Eng. Online20212012410.1186/s12938‑021‑00860‑033653371
     [Google Scholar]
  25. WeiN. Chao-yangG. Wen-mingZ. Ze-yuanL. Yong-qiangS. Shun-baiZ. KaiZ. Yan-chaoM. Hai-hongZ. A ubiquitin-related gene signature for predicting prognosis and constructing molecular subtypes in osteosarcoma.Front. Pharmacol.20221390444810.3389/fphar.2022.90444836060009
     [Google Scholar]
  26. RajendraR. MalegaonkarD. PungaliyaP. MarshallH. RasheedZ. BrownellJ. LiuL.F. LutzkerS. SaleemA. RubinE.H. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.J. Biol. Chem.200427935364403644410.1074/jbc.C40030020015247280
     [Google Scholar]
  27. ZhangX. HuoC. LiuY. SuR. ZhaoY. LiY. Mechanism and disease association with a ubiquitin conjugating E2 enzyme: UBE2L3.Front. Immunol.20221379361010.3389/fimmu.2022.79361035265070
     [Google Scholar]
  28. FuB. LiS. WangL. BermanM.A. DorfM.E. The ubiquitin conjugating enzyme UBE2L3 regulates TNFα-induced linear ubiquitination.Cell Res.201424337637910.1038/cr.2013.13324060851
     [Google Scholar]
  29. CortizoA.M. BruzzoneL. MolinuevoS. EtcheverryS.B. A possible role of oxidative stress in the vanadium-induced cytotoxicity in the MC3T3E1 osteoblast and UMR106 osteosarcoma cell lines.Toxicology20001472899910.1016/S0300‑483X(00)00181‑510874156
     [Google Scholar]
  30. CondosT.E.C. DunkerleyK.M. FreemanE.A. BarberK.R. AguirreJ.D. ChauguleV.K. XiaoY. KonermannL. WaldenH. ShawG.S. Synergistic recruitment of UbcH7~Ub and phosphorylated Ubl domain triggers parkin activation.EMBO J.20183723e10001410.15252/embj.201810001430446597
     [Google Scholar]
  31. CamarilloG.F. GoyonE.I. ZuñigaR.B. SalasL.A.S. EscárcegaA.E.P. Yamamoto-FurushoJ.K. Gene expression profiling of mediators associated with the inflammatory pathways in the intestinal tissue from patients with ulcerative colitis.Mediators Inflamm.2020202011110.1155/2020/923897032410873
     [Google Scholar]
  32. GarvaR. ThepmaleeC. YasamutU. SudsawardS. GuazzelliA. RajendranR. TongmuangN. KhunchaiS. MeysamiP. LimjindapornT. YenchitsomanusP. MuttiL. Krstic-DemonacosM. DemonacosC. Sirtuin family members selectively regulate autophagy in osteosarcoma and mesothelioma cells in response to cellular stress.Front. Oncol.2019994910.3389/fonc.2019.0094931608237
     [Google Scholar]
  33. KurzT. TermanA. BrunkU.T. Autophagy, ageing and apoptosis: The role of oxidative stress and lysosomal iron.Arch. Biochem. Biophys.2007462222023010.1016/j.abb.2007.01.01317306211
     [Google Scholar]
  34. HanusJ. AndersonC. WangS. RPE necroptosis in response to oxidative stress and in AMD.Ageing Res. Rev201524Pt B28629810.1016/j.arr.2015.09.002
     [Google Scholar]
/content/journals/pra/10.2174/0115748928297557240212112531
Loading
UBE2L3 Suppresses Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression
Recent Patents on Anti-Cancer Drug Discovery 20, 102 (2025); https://doi.org/10.2174/0115748928297557240212112531
/content/journals/pra/10.2174/0115748928297557240212112531
/content/journals/pra/10.2174/0115748928297557240212112531
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): apoptosis; necroptosis; Osteosarcoma; oxidative stress; ROS; UBE2L3

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test